GEMFIBROZIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H22O3
Molecular Weight	250.3334
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1

InChI

InChIKey=HEMJJKBWTPKOJG-UHFFFAOYSA-N

InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H22O3
Molecular Weight	250.3334
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01241
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately). Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Gemfibrozil is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Solute carrier organic anion transporter family member 1B1 32 Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16316932	Inhibitor 8297	12.5 µM [Ki]
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16299161	Inhibitor 8297	30.0 µM [IC50]
Cytochrome P450 2C8 18 Target ID: CHEMBL3721 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176562	Inhibitor 8297	30.4 µM [Ki]
Peroxisome proliferator-activated receptor alpha 62 Target ID: CHEMBL239 Sources: http://www.drugbank.ca/drugs/DB01241	Agonist 2678	59.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipidemia 80 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Primary		Approved 8429	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 1981
Coronary heart disease 41 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Preventing		Approved 8429	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 1981

C_max

Value	Dose	Co-administered	Analyte	Population
28 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17400 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01736254	600 mg single, oral dose: 600 mg route of administration: oral experiment type: single co-administered:		GEMFIBROZIL plasma	Homo sapiens population: healthy age: sex: food status:

AUC

Value	Dose	Co-administered	Analyte	Population
104 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	Disc. AE: Depression, Flushing... AEs leading to discontinuation/dose reduction: Depression (1.1%) Flushing (1.1%) Nausea (2.2%) Vomiting (1.1%) Rash (1.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	Disc. AE: Abdominal cramps, Abnormal liver function tests... AEs leading to discontinuation/dose reduction: Abdominal cramps Abnormal liver function tests Diarrhea CPK increased Joint pain Muscle pain Nausea Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13

AEs

AE	Significance	Dose	Population
Depression	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Flushing	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Rash	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Vomiting	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Nausea	2.2% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Abdominal cramps	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Abnormal liver function tests	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
CPK increased	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Diarrhea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Joint pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Muscle pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Nausea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Vomiting	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 788 OATP2B1 123 OATP1B3 706 OAT3 642 MRP2 383 P-gp 1461 CYP2C8 911 CYP2C19 1478 CYP1A2 1524 CYP2A6 707 CYP2E1 882	P-gp 1537 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2A6 739	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/	no
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/14698041/	no
OAT3 644	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/21383204/\|https://pubmed.ncbi.nlm.nih.gov/17455113/	yes [Ki 1.5 uM]
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/23139378/\|https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes [Ki 14.2 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/	yes [Ki 5.8 uM]	yes (co-administration study) Comment: [PMID:11719730]:Gemfibrozil modestly increases the plasma concentrations of glimepiride. This may be caused by inhibition of CYP2C9. Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
CYP2C19 1553	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
CYP2C8 965	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/	yes	yes (co-administration study) Comment: [PMID:22472994]: CYP2C8 inactivation by gemfibrozil caused dose-dependent increases in AUC of repaglinide Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/

Drug as victim

Target	Modality	Activity
UGT2B7 389	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	major
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/	no
UGT1A10 291	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A4 347	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A6 307	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A7 236	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A8 283	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT2B15 203	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A1 418	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A3 422	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A9 380	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B17 213	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B4 249	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5296	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5296
ChemicalBook	CB9154247	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9154247
MolPort	MolPort-001-794-413	https://www.molport.com/shop/molecule-link/MolPort-001-794-413
Selleck Chemicals	Gemfibrozil(Lopid)	http://www.selleckchem.com/products/Gemfibrozil(Lopid).html
ZINC	ZINC000001530641	http://zinc15.docking.org/substances/ZINC000001530641
eMolecules	538915	https://www.emolecules.com/cgi-bin/more?vid=538915

PubMed

Title	Date	PubMed
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.	2001	11795072
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction.	2001	11552053
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.	2001 Aug	11764054
[Fatal rhabdomyolysis caused by cerivastatin].	2001 Aug	11584446
Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine.	2001 Aug	11483622
Bayer decides to withdraw cholesterol lowering drug.	2001 Aug 18	11509419
Baycol withdrawn from market.	2001 Aug 21	11521677
Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals.	2001 Aug 28	11522369
[Lipid-lowering drugs].	2001 Dec	11778457
Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.	2001 Dec	11733637
Treatment for the procoagulant state in type 2 diabetes.	2001 Dec	11727398
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?	2001 Dec	11722675
Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri.	2001 Dec 14	11771838
Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial.	2001 Dec 20	11788126
[Fibrates in the secondary prevention of ischemic cardiopathy].	2001 Jan-Mar	11565320
Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.	2001 Jul	11583069
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].	2001 Jul	11515276
Fenofibrate and warfarin interaction.	2001 Jul	11444587
Postprandial remnant-like lipoproteins in hypertriglyceridemia.	2001 Jul	11443178
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001 Jul 7	11454380
Statin-fibrate combination therapy.	2001 Jul-Aug	11485144
Normocholesterolaemic dysslipidaemia: is there a role for fibrates?	2001 Jun 4	11453341
Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells.	2001 Nov	11816722
Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.	2001 Nov	11731925
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.	2001 Nov	11719730
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.	2001 Nov	11715936
PPARS, metabolic disease and atherosclerosis.	2001 Nov	11712864
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.	2001 Nov	11701466
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?	2001 Nov	11694861
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?	2001 Nov	11684067
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.	2001 Nov	11602509
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001 Nov 24	11734263
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001 Nov 24	11734262
Statin-associated myopathy.	2001 Nov 5	11758079
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.	2001 Oct	11586485
Cyclic nucleotides in platelets of genetically hypertriglyceridemic and hypertensive rats. Thrombin and nitric oxide responses are unrelated to plasma triglyceride levels.	2001 Oct 1	11583736
[Cerivastatin and gemfibrozil: a dangerous combination].	2001 Oct 15	11602128
Molecular basis for the effect of lipid lowering drugs on growth factors after de-endothelialization.	2001 Sep	11780395
[Cholestatic hepatitis caused by gemfibrozil].	2001 Sep	11767440
Cerivastatin and gemfibrozil-associated rhabdomyolysis.	2001 Sep	11573847
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.	2001 Sep	11570656
Is the relationship between adipose tissue and waist girth altered by weight loss in obese men?	2001 Sep	11557833
New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.	2001 Sep	11487447
[Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].	2001 Sep 15	11562335
Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats.	2001 Sep 15	11551527
Bayer pulls cerivastatin (Baycol) from market.	2001 Sep 4	11563216
[Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].	2001 Sep-Oct	11795020
Therapy and clinical trials.	2002 Feb	11790971
Sexual dysfunction secondary to gemfibrozil.	2002 Jan	11794424
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.	2002 Jan 28	11802751

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meals

Route of Administration: Oral

In Vitro Use Guide

Sustained potent reduction of [Ca²⁺]i in cultured rat VSMCs was observed with Gemfibrozil 50mg/L

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:19:58 GMT 2023` Edited by `admin` on `Fri Dec 15 15:19:58 GMT 2023`
Record UNII	Q8X02027X3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GEMFIBROZIL

Official Name

English

GEMFIBROZIL [IARC]

Common Name

English

Gemfibrozil [WHO-DD]

Common Name

English

GEMFIBROZIL [HSDB]

Common Name

English

2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID

Systematic Name

English

gemfibrozil [INN]

Common Name

English

GEMFIBROZIL [EP MONOGRAPH]

Common Name

English

GEMFIBROZIL [MART.]

Common Name

English

GEMFIBROZIL [USAN]

Common Name

English

GEMFIBROZIL [USP-RS]

Common Name

English

GEMFIBROZIL [JAN]

Common Name

English

NSC-757024

Code

English

GEMFIBROZIL [ORANGE BOOK]

Common Name

English

GEMFIBROZIL [MI]

Common Name

English

GEMFIBROZIL [INCI]

Common Name

English

CI-719

Code

English

GEMFIBROZIL [USP MONOGRAPH]

Common Name

English

PENTANOIC ACID, 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYL-

Common Name

English

LOPID

Brand Name

English

GEMFIBROZIL [VANDF]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

834821